Pharmaceuticals & Therapeutics

A new study reveals consumer interest in regenerative agriculture is surging, but it's driven by personal health and nutrition, not just environmentalism.

In one of America's wealthiest corridors, a hunger crisis is growing. A unique partnership shows how corporate, non-profit, and community forces unite to help.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

Brewer Science's acquisition of a key chemical unit is more than a deal; it's a strategic fortification of the global semiconductor supply chain.

A new initiative promises to help rural clinics access federal funds for telehealth, but it’s also a savvy growth play for the tech company behind it.

A small Colorado firm's award-winning floor, made from waste shells and backed by the military, signals a major shift in our reliance on fossil fuels.

As medical spas boom, companies like Cosmedical are empowering doctors to sell their own brands, betting on curated regimens to boost both patient results and profits.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

With the hire of a crisis-tested litigator, law firm SBSB is betting on deep operational insight to navigate the increasingly treacherous waters of maritime law.

Beyond amyloid plaques, a new therapy tackles Alzheimer's by reducing inflammation. Longeveron's latest data offers a glimpse into a regenerative future.

New real-time imaging gives surgeons a 3D molecular map of cancer in the OR, poised to end the emotional and physical toll of reoperations for many.

Takeda is deploying Boltz's frontier AI across its labs, betting that AI agents can accelerate medicine by acting as a creative partner for scientists.

A quiet revolution is underway in animal feed, with enzymes driving a $4.6B market. This isn't just about cost; it's a tech-fueled shift to profitability.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

The K-beauty giant's massive Amazon sale is more than just discounts; it's a strategic play to launch products, capture new markets, and solidify its e-commerce dominance.

A silent health crisis affecting a billion women is becoming a major economic focus. One firm's move to train a new workforce signals a paradigm shift.

With $4.6M in funding, a San Diego startup is challenging the multi-million dollar surgical robotics market with a handheld, AI-powered device.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

The appointment of Bethany Sensenig, a veteran of PE-backed turnarounds, signals CenExel is preparing for a major push to dominate the clinical research market.

With Hillary Aiken leading its new philanthropic arm, 23andMe Research Institute bets on private giving to accelerate its 'public good' DNA revolution.